Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-21-015862
Filing Date
2021-11-15
Accepted
2021-11-15 07:19:53
Documents
48
Period of Report
2021-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q plx-20210930x10q.htm   iXBRL 10-Q 1093841
2 EX-31.1 plx-20210930xex31d1.htm EX-31.1 10033
3 EX-31.2 plx-20210930xex31d2.htm EX-31.2 10393
4 EX-32.1 plx-20210930xex32d1.htm EX-32.1 6098
5 EX-32.2 plx-20210930xex32d2.htm EX-32.2 6124
6 GRAPHIC plx-20210930x10q005.jpg GRAPHIC 62538
7 GRAPHIC plx-20210930x10q006.jpg GRAPHIC 66284
8 GRAPHIC plx-20210930x10q007.jpg GRAPHIC 35036
  Complete submission text file 0001558370-21-015862.txt   4334286

Data Files

Seq Description Document Type Size
9 EX-101.SCH plx-20210930.xsd EX-101.SCH 32665
10 EX-101.CAL plx-20210930_cal.xml EX-101.CAL 36604
11 EX-101.DEF plx-20210930_def.xml EX-101.DEF 138653
12 EX-101.LAB plx-20210930_lab.xml EX-101.LAB 224933
13 EX-101.PRE plx-20210930_pre.xml EX-101.PRE 212521
14 EXTRACTED XBRL INSTANCE DOCUMENT plx-20210930x10q_htm.xml XML 490689
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33357 | Film No.: 211406300
SIC: 2836 Biological Products, (No Diagnostic Substances)